Avinza

(Morphine hydrochloride)

ApprovedSmall molecule

Avinza is one of 120 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

119

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseRecruiting

Interstitial Lung DiseaseActive, not recruiting

Cesarean SectionActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Recruiting

Interstitial Lung DiseaseApproved

Active, not recruiting

Cesarean SectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

119 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Avinza

HHikma Pharmaceuticals LLC

Approved

1 2

Lunsekimig

Sanofi

Phase 3

3 3

CM310

KKeymed Biosciences Co.Ltd

Phase 3

1 4

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 5

Tozorakimab

AstraZeneca

Phase 3

2 6

Astegolimab

Roche

Phase 3

2 7

CM512

KKeymed Biosciences Co.Ltd

Phase 2

1 8

RLS-0071

RReAlta Life Sciences, Inc.

Phase 2

1 9

Calciferol

Duragesic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Chronic Obstructive Pulmonary Disease

NCT04427826

Clinical

Trials by Indication[1]

Phase II Clinical Trial2 trials

Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery

Recruiting· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 2·NCT06467409·150 enrolled

Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery

Completed· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 2·NCT06204120·150 enrolled

Perioperative Analgesia1 trial

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

Unknown status·QQianfoshan Hospital·Phase 4·NCT05848635·88 enrolled

Pain Management1 trial

A Comparison of Three Regimens of Acute Pain Management: Methoxyflurane; Intranasal Fentanyl; Intravenous Morphine

Completed·OOslo University Hospital·Phase 3·NCT05137184·338 enrolled

Cesarean Section1 trial

Compared With Different Method for Postcesarean Section Analgesia

Completed·—·N/A·NCT05405049·46 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa

Recruiting·UUniversity Hospital, Grenoble·Phase 1/2·NCT04427826·24 enrolled

5 more indications

Interstitial Lung Disease1 trial

Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease

Completed·UUniversity of Aarhus·Phase 4·NCT02622022·36 enrolled

Thoracic Surgery1 trial

Comparison of Tramadol, Pethidine and Morphine in the Treatment of Pain After Thoracic Surgery

Unknown status·—·Phase 4·NCT06172920·45 enrolled

Pulmonary Fibrosis1 trial

Morphine for Dyspnea in Pulmonary Fibrosis

Unknown status·MMedical University of Gdansk·Phase 3·NCT04497831·20 enrolled

Idiopathic Scoliosis1 trial

Comparison of the Efficacy of Ketamine in Pediatric Patients With Idiopathic Scoliosis After Surgery

Completed·FFundació Sant Joan de Déu·Phase 2·NCT02571491·48 enrolled

Postoperative Analgesia1 trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Nalbuphine Versus Morphine for the Treatment of Postoperative Analgesia

Completed·YYangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd·Phase 3·NCT06949852·289 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 18, 1984

DURAMORPH PF

NDA NDA018565

Sep 12, 1989

MS CONTIN

NDA NDA019516

Jul 12, 1990

MORPHINE SULFATE (AUTOINJECTOR)

NDA NDA019999

Oct 30, 1992

MORPHINE SULFATE

NDA NDA019917

Oct 30, 1992

MORPHINE SULFATE

NDA NDA019916

Nov 23, 1994

ORAMORPH SR

NDA NDA019977

Jul 3, 1996

MORPHINE SULFATE

NDA NDA020631

Mar 20, 2002

AVINZA

NDA NDA021260

May 18, 2004

DEPODUR

NDA NDA021671

Apr 20, 2007

KADIAN

NDA NDA020616

Mar 17, 2008

MORPHINE SULFATE

NDA NDA022207

Mar 17, 2008

MORPHINE SULFATE

NDA NDA022195

Jun 23, 2011

MORPHINE SULFATE

NDA NDA201517

Nov 14, 2011

MORPHINE SULFATE

NDA NDA202515

Oct 2, 2015

MORPHABOND ER

NDA NDA206544

Jan 9, 2017

ARYMO ER

NDA NDA208603

May 29, 2026

MORPHINE SULFATE

NDA NDA204223

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Morphine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Morphine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Morphine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA204223). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Hikma Pharmaceuticals LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHikma Pharmaceuticals LLC

Avinza

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Phase II Clinical Trial2 trials

Perioperative Analgesia1 trial

Pain Management1 trial

Cesarean Section1 trial

Chronic Obstructive Pulmonary Disease1 trial

Interstitial Lung Disease1 trial

Thoracic Surgery1 trial

Pulmonary Fibrosis1 trial

Idiopathic Scoliosis1 trial

Postoperative Analgesia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News